Abstinence self-efficacy in people with severe mental illness von O'Hare, Thomas, Ph.D, Shen, Ce, Ph.D

Volltext

Finite data rigidity for one-dimensional expanding maps von O’HARE, THOMAS ALOYSIUS

Volltext

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion von Heaton, William L., Senina, Anna V., Pomicter, Anthony D., Salama, Mohamed E., Clair, Phillip M., Yan, Dongqing, Bell, Russell N., Gililland, Jeremy M., Prchal, Josef T., O’Hare, Thomas, Deininger, Michael W.

Volltext

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia von O'Hare, Thomas, Eide, Christopher A., Deininger, Michael W.N.

Volltext

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias von Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael W.N, Talpaz, Moshe

Volltext

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance von O'Hare, Thomas, Shakespeare, William C., Zhu, Xiaotian, Eide, Christopher A., Rivera, Victor M., Wang, Frank, Adrian, Lauren T., Zhou, Tianjun, Huang, Wei-Sheng, Xu, Qihong, Metcalf, Chester A., Tyner, Jeffrey W., Loriaux, Marc M., Corbin, Amie S., Wardwell, Scott, Ning, Yaoyu, Keats, Jeffrey A., Wang, Yihan, Sundaramoorthi, Raji, Thomas, Mathew, Zhou, Dong, Snodgrass, Joseph, Commodore, Lois, Sawyer, Tomi K., Dalgarno, David C., Deininger, Michael W.N., Druker, Brian J., Clackson, Tim

Volltext

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia von Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., O’Hare, Thomas

Volltext

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl von Gregory, Mark A, Phang, Tzu L, Neviani, Paolo, Alvarez-Calderon, Francesca, Eide, Christopher A, O'Hare, Thomas, Zaberezhnyy, Vadym, Williams, Richard T, Druker, Brian J, Perrotti, Danilo, Degregori, James

Volltext

Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening von TYNER, Jeffrey W, YANG, Wayne F, KOVACSOVICS, Tibor, GOTLIB, Jason R, OH, Stephen T, DEININGER, Michael W, MICHEL ZWAAN, Christian, DEN BOER, Monique L, VAN DEN HEUVEL-EIBRINK, Marry M, O'HARE, Thomas, DRUKER, Brian J, LORIAUX, Marc M, BANKHEAD, Armand, GUANG FAN, FLETCHER, Luke B, BRYANT, Jade, GLOVER, Jason M, CHANG, Bill H, SPURGEON, Stephen E, FLEMING, William H

Volltext

JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera von Patel, Ami B., Franzini, Anca, Leroy, Emilie, Kim, Soo Jin, Pomicter, Anthony D., Genet, Lidvine, Xiao, Michael, Yan, Dongqing, Ahmann, Jonathan M., Agarwal, Archana M., Clair, Phillip, Addada, Juanah, Lambert, Jonathan, Salmon, Matthew, Gleich, Gerald J., Cross, Nicholas C.P., Constantinescu, Stefan N., O'Hare, Thomas, Prchal, Josef T., Deininger, Michael W.

Volltext

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships von Khorashad, Jamshid S., Kelley, Todd W., Szankasi, Philippe, Mason, Clinton C., Soverini, Simona, Adrian, Lauren T., Eide, Christopher A., Zabriskie, Matthew S., Lange, Thoralf, Estrada, Johanna C., Pomicter, Anthony D., Eiring, Anna M., Kraft, Ira L., Anderson, David J., Gu, Zhimin, Alikian, Mary, Reid, Alistair G., Foroni, Letizia, Marin, David, Druker, Brian J., O'Hare, Thomas, Deininger, Michael W.

Volltext

An illicit economy: Scavenging and recycling of medical waste von Patwary, Masum A., O’Hare, William Thomas, Sarker, M.H.

Volltext

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations von Bradeen, Heather A., Eide, Christopher A., O'Hare, Thomas, Johnson, Kara J., Willis, Stephanie G., Lee, Francis Y., Druker, Brian J., Deininger, Michael W.

Volltext

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants von O'HARE, Thomas, WALTERS, Denise K, DRUKER, Brian J, STOFFREGEN, Eric P, TAIPING JIA, MANLEY, Paul W, MESTAN, Jürgen, COWAN-JACOB, Sandra W, LEE, Francis Y, HEINRICH, Michael C, DEININGER, Michael W. N

Volltext

ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation? von Yan, Dongqing, Pomicter, Anthony D, O'Hare, Thomas, Deininger, Michael W

Volltext

SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA von Yan, Dongqing, Franzini, Anca, Pomicter, Anthony D, Halverson, Brayden J, Antelope, Orlando, Mason, Clinton C, Ahmann, Jonathan M, Senina, Anna V, Vellore, Nadeem A, Jones, Courtney L, Zabriskie, Matthew S, Than, Hein, Xiao, Michael J, van Scoyk, Alexandria, Patel, Ami B, Clair, Phillip M, Heaton, William L, Owen, Shawn C, Andersen, Joshua L, Egbert, Christina M, Reisz, Julie A, D'Alessandro, Angelo, Cox, James E, Gantz, Kevin C, Redwine, Hannah M, Iyer, Siddharth M, Khorashad, Jamshid S, Rajabi, Nima, Olsen, Christian A, O'Hare, Thomas, Deininger, Michael W

Volltext

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia von O'HARE, Thomas, DEININGER, Michael W. N, EIDE, Christopher A, CLACKSON, Tim, DRUKER, Brian J

Volltext

Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy von Buetti-Dinh, Antoine, O'Hare, Thomas, Friedman, Ran

Volltext

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia von Packer, Leisl M., Rana, Sareena, Hayward, Robert, O'Hare, Thomas, Eide, Christopher A., Rebocho, Ana, Heidorn, Sonja, Zabriskie, Matthew S., Niculescu-Duvaz, Ion, Druker, Brian J., Springer, Caroline, Marais, Richard

Volltext

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile von Eide, Christopher A, Adrian, Lauren T, Tyner, Jeffrey W, Mac Partlin, Mary, Anderson, David J, Wise, Scott C, Smith, Bryan D, Petillo, Peter A, Flynn, Daniel L, Deininger, Michael W N, O'Hare, Thomas, Druker, Brian J

Volltext